Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset
BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival
Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority
Medtech M&A may pick up after mixed start to 2024, analysts
*please scroll down for all the latest news*
